Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlba Marina Gimenezen_US
dc.contributor.authorLuciana Chagas Limaen_US
dc.contributor.authorKatia Sanches Françosoen_US
dc.contributor.authorPriscila M.A. Denapolien_US
dc.contributor.authorRaquel Panatierien_US
dc.contributor.authorDaniel Y. Bargierien_US
dc.contributor.authorJean Michel Thibergeen_US
dc.contributor.authorChiara Andolinaen_US
dc.contributor.authorFrancois Nostenen_US
dc.contributor.authorLaurent Reniaen_US
dc.contributor.authorRuth S. Nussenzweigen_US
dc.contributor.authorVictor Nussenzweigen_US
dc.contributor.authorRogerio Aminoen_US
dc.contributor.authorMauricio M. Rodriguesen_US
dc.contributor.authorIrene S. Soaresen_US
dc.contributor.otherUniversidade Federal de Sao Pauloen_US
dc.contributor.otherUniversidade de Sao Paulo - USPen_US
dc.contributor.otherInstitut Pasteur, Parisen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherA-Star, Singapore Immunology Networken_US
dc.contributor.otherNYU School of Medicineen_US
dc.identifier.citationFrontiers in Immunology. Vol.8, No.OCT (2017)en_US
dc.description.abstract© 2017 Gimenez, Lima, Françoso, Denapoli, Panatieri, Bargieri, Thiberge, Andolina, Nosten, Renia, Nussenzweig, Nussenzweig, Amino, Rodrigues and Soares. Plasmodium vivax is the most common species that cause malaria outside of the African continent. The development of an efficacious vaccine would contribute greatly to control malaria. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (CSP), we demonstrated the possibility of eliciting strong antibody-mediated immune responses to each of the three allelic forms of P. vivax CSP (PvCSP). In the present study, recombinant proteins representing the PvCSP alleles (VK210, VK247, and P. vivax-like), as well as a hybrid polypeptide, named PvCSP-All epitopes, were generated. This hybrid containing the conserved C-terminal of the PvCSP and the three variant repeat domains in tandem were successfully produced in the yeast Pichia pastoris. After purification and biochemical characterization, they were used for the experimental immunization of C57BL/6 mice in a vaccine formulation containing the adjuvant Poly(I:C). Immunization with a recombinant protein expressing all three different allelic forms in fusion elicited high IgG antibody titers reacting with all three different allelic variants of PvCSP. The antibodies targeted both the C-terminal and repeat domains of PvCSP and recognized the native protein on the surface of P. vivax sporozoites. More importantly, mice that received the vaccine formulation were protected after challenge with chimeric Plasmodium berghei sporozoites expressing CSP repeats of P. vivax sporozoites (Pb/PvVK210). Our results suggest that it is possible to elicit protective immunity against one of the most common PvCSP alleles using soluble recombinant proteins expressed by P. pastoris. These recombinant proteins are promising candidates for clinical trials aiming to develop a multiallele vaccine against P. vivax malaria.en_US
dc.rightsMahidol Universityen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleVaccine containing the three allelic variants of the Plasmodium vivax circumsporozoite antigen induces protection in mice after challenge with a transgenic rodent malaria parasiteen_US
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.